Romênia - romeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

hwi pharma services gmbh - germania - salmeterolum+fluticasonum - pulb. de inhal. unidoza - 50micrograme/250micrograme - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r

Romênia - romeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

hwi pharma services gmbh - germania - salmeterolum+fluticasonum - pulb. de inhal. unidoza - 50micrograme/500micrograme - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r

Romênia - romeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gp grenzach produktions gmbh - germania - denumirea comuna internationala - caps. moi vag. - 500 mg - antiinfectioase (excl. combinatii cu corticosteroizi) derivati de imidazol

União Europeia - romeno - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - alți agenți antineoplazici - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

União Europeia - romeno - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agenți antineoplazici - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Romênia - romeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

terapia s.a - romania - isotretinoinum - caps. moi - 10mg - preparate de uz sistemic pt. trat. acneei retinoizi pentru tratamentul acneei

Romênia - romeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

terapia s.a - romania - isotretinoinum - caps. moi - 20mg - preparate de uz sistemic pt. trat. acneei retinoizi pentru tratamentul acneei

Romênia - romeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

the wellcome foundation ltd. - aciclovirum - crema - 50 mg/g - chimioterapice de uz local antivirale

Romênia - romeno - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

alcon - couvreur n.v. - belgia - latanoprostum - pic. oft., sol. - 50micrograme/ml - antiglaucomatoase si miotice analogi de prostaglandine

União Europeia - romeno - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrita, reumatoida - imunosupresoare - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.